PURPOSE: The tetraspan protein epithelial membrane protein-2 (EMP2) has been shown to regulate the surface display and signaling from select integrin pairs, and it was recently identified as a prognostic biomarker in human endometrial cancer. In this study, we assessed the role of EMP2 in human ovarian cancer. EXPERIMENTAL DESIGN: We examined the expression of EMP2 within a population of women with ovarian cancer using tissue microarray assay technology. We evaluated the efficacy of EMP2-directed antibody therapy using a fully human recombinant bivalent antibody fragment (diabody) in vitro and ovarian cancer xenograft models in vivo. RESULTS: EMP2 was found to be highly expressed in >70% of serous and endometrioid ovarian tumors compared with nonmalignant ovarian epithelium using a human ovarian cancer tissue microarray. Using anti-EMP2 diabody, we evaluated the in vitro response of nine human ovarian cancer cell lines with detectable EMP2 expression. Treatment of human ovarian cancer cell lines with anti-EMP2 diabodies induced cell death and retarded cell growth, and these response rates correlated with cellular EMP2 expression. We next assessed the effects of anti-EMP2 diabodies in mice bearing xenografts from the ovarian endometrioid carcinoma cell line OVCAR5. Anti-EMP2 diabodies significantly suppressed tumor growth and induced cell death in OVCAR5 xenografts. CONCLUSIONS: These findings indicate that EMP2 is expressed in the majority of ovarian tumors and may be a feasible target in vivo. (c) 2010 AACR.
PURPOSE: The tetraspan protein epithelial membrane protein-2 (EMP2) has been shown to regulate the surface display and signaling from select integrin pairs, and it was recently identified as a prognostic biomarker in humanendometrial cancer. In this study, we assessed the role of EMP2 in humanovarian cancer. EXPERIMENTAL DESIGN: We examined the expression of EMP2 within a population of women with ovarian cancer using tissue microarray assay technology. We evaluated the efficacy of EMP2-directed antibody therapy using a fully human recombinant bivalent antibody fragment (diabody) in vitro and ovarian cancer xenograft models in vivo. RESULTS:EMP2 was found to be highly expressed in >70% of serous and endometrioid ovarian tumors compared with nonmalignant ovarian epithelium using a humanovarian cancer tissue microarray. Using anti-EMP2 diabody, we evaluated the in vitro response of nine humanovarian cancer cell lines with detectable EMP2 expression. Treatment of humanovarian cancer cell lines with anti-EMP2 diabodies induced cell death and retarded cell growth, and these response rates correlated with cellular EMP2 expression. We next assessed the effects of anti-EMP2 diabodies in mice bearing xenografts from the ovarian endometrioid carcinoma cell line OVCAR5. Anti-EMP2 diabodies significantly suppressed tumor growth and induced cell death in OVCAR5 xenografts. CONCLUSIONS: These findings indicate that EMP2 is expressed in the majority of ovarian tumors and may be a feasible target in vivo. (c) 2010 AACR.
Authors: Dejun Shen; Helena R Chang; Zugen Chen; Jianbo He; Victor Lonsberry; Yahya Elshimali; David Chia; David Seligson; Lee Goodglick; Stanley F Nelson; Jeffrey A Gornbein Journal: Biochem Biophys Res Commun Date: 2005-01-07 Impact factor: 3.575
Authors: Kostyantyn Krysan; Farrukh H Merchant; Li Zhu; Mariam Dohadwala; Jie Luo; Ying Lin; Nathalie Heuze-Vourc'h; Mehis Põld; David Seligson; David Chia; Lee Goodglick; Hejing Wang; Robert Strieter; Sherven Sharma; Steven Dubinett Journal: FASEB J Date: 2003-11-03 Impact factor: 5.191
Authors: David B Seligson; Steve Horvath; Matthew A McBrian; Vei Mah; Hong Yu; Sheila Tze; Qun Wang; David Chia; Lee Goodglick; Siavash K Kurdistani Journal: Am J Pathol Date: 2009-04-06 Impact factor: 4.307
Authors: Tove Olafsen; Giselle J Tan; Chia-Wei Cheung; Paul J Yazaki; Jinha M Park; John E Shively; Lawrence E Williams; Andrew A Raubitschek; Michael F Press; Anna M Wu Journal: Protein Eng Des Sel Date: 2004-06-08 Impact factor: 1.650
Authors: Shawn A Morales; Sergey Mareninov; Madhuri Wadehra; Lily Zhang; Lee Goodglick; Jonathan Braun; Lynn K Gordon Journal: Invest Ophthalmol Vis Sci Date: 2008-05-09 Impact factor: 4.799
Authors: Kaori Shimazaki; Eric J Lepin; Bo Wei; Agnes K Nagy; Catherine P Coulam; Sergey Mareninov; Maoyong Fu; Anna M Wu; James D Marks; Jonathan Braun; Lynn K Gordon; Madhuri Wadehra Journal: Clin Cancer Res Date: 2008-11-15 Impact factor: 12.531
Authors: Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon Journal: Exp Eye Res Date: 2012-06-19 Impact factor: 3.467
Authors: Kunal S Patel; Sameer Kejriwal; Michel M Sun; Samasuk Thammachantha; Courtney Duong; Ann Chan; Nina Cherian; Prasanth Romiyo; Lynn K Gordon; William Yong; Madhuri Wadehra; Isaac Yang Journal: J Neurooncol Date: 2020-01-24 Impact factor: 4.130
Authors: Maoyong Fu; Erin L Maresh; Gustavo F Helguera; Meagan Kiyohara; Yu Qin; Negin Ashki; Tracy R Daniels-Wells; Najib Aziz; Lynn K Gordon; Jonathan Braun; Yahya Elshimali; Robert A Soslow; Manuel L Penichet; Lee Goodglick; Madhuri Wadehra Journal: Mol Cancer Ther Date: 2014-01-21 Impact factor: 6.261
Authors: Lawrance K Chung; Panayiotis E Pelargos; Ann M Chan; Joanna V Demos; Carlito Lagman; John P Sheppard; Thien Nguyen; Yu-Ling Chang; Seyed A Hojat; Robert M Prins; Linda M Liau; Leia Nghiemphu; Albert Lai; Timothy F Cloughesy; William H Yong; Lynn K Gordon; Madhuri Wadehra; Isaac Yang Journal: Brain Tumor Pathol Date: 2017-09-08 Impact factor: 3.298
Authors: Maoyong Fu; Sarah Brewer; Tove Olafsen; Anna M Wu; Lynn K Gordon; Jonathan Said; Jonathan Braun; Madhuri Wadehra Journal: Mol Imaging Biol Date: 2013-02 Impact factor: 3.488